Market Overview

Is Allergan Going After Valeant's Eye Surgery Assets?

Share:
Is Allergan Going After Valeant's Eye Surgery Assets?

It is no secret that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) needs to divest some of its assets to give the company sufficient liquidity to reduce its debt load before it becomes potentially unmanageable.

The Wall Street Journal reported in early November that the pharmaceutical company has been looking for a buyer to acquire its eye-surgery equipment business, and the price tag attached to a deal could be as much as $2.5 billion.

On Thursday, chatter of a potential deal surfaced that contributed to a brief spike in Valeant's stock, which was trading higher by more than 1 percent at $18.20 — just a few dollars removed from its multi-year lows of below $15 per share.

According to a Bloomberg report, Allergan plc Ordinary Shares (NYSE: AGN) could team up with the private equity firm TPG to buy Valeant's eye-surgery business.

Benzinga reached out to Allergan for commentary. he company responded that as a matter of company policy, it does not comment on market rumors or speculation.

Posted-In: Vaeant Divestments ValeantBiotech News Rumors Asset Sales Media General Best of Benzinga

 

Related Articles (AGN + VRX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Assessing The Legitimacy Of The Biotech ETF Bounce

10 Notable Stocks Trading Ex-Dividend Monday, November 21